Fragile X Syndrome Research Study
Currently enrolling children and adolescents age 3 to 17 years of age with Fragile X syndrome who are also experiencing behavioral-related issues.
Why is this Medical Research Study Important?
The purpose of this study is to assess the effectiveness and safety of investigational cannabidiol (CBD) administered as a transdermal gel (ZYN002) for children and adolescents with Fragile X syndrome (FXS).
Children and adolescents with FXS often experience behavioral symptoms such as anxiety (particularly social anxiety/avoidance), irritability, tantrums and social unresponsiveness, which can be challenging, not only for the patients, but also their families. ZYN002 may help to reduce these symptoms and has shown potentially promising results in prior studies.
To help us learn more about the safety and effectiveness of ZYN002, volunteers are needed for the RECONNECT study. Qualified participants will receive study drug or placebo and will help researchers learn if ZYN002 can help.
Qualified Participants Must:
Be experiencing behavioral symptoms of Fragile X syndrome such as social anxiety/avoidance, irritability, and social unresponsiveness.
